Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5330 - Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Ida Buhl


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


I.K. Buhl1, G.U. Carlsson2, P. Saksena3, B. Gustavsson2, I.J. Christensen4, A. Edsjö5, A. Hansen6, S. Knudsen7, P.B. Jensen8, Y. Wettergren2

Author affiliations

  • 1 Denmark, Oncology Venture, 2970 - Hørsholm/DK
  • 2 Gastrointestinal Oncology, Sahlgrenska University Hospital, 41345 - Göteborg/SE
  • 3 Pathology, Sahlgrenska University Hospital, 41345 - Göteborg/SE
  • 4 Gastro Unit, Hvidovre Hospital, 2650 - Hvidovre/DK
  • 5 Department Of Clinical Genetics And Pathology, Region Skåne, Malmö/SE
  • 6 Denmark, Oncology Venture, DK-2970 - Hørsholm/DK
  • 7 Inc, Oncology Venture, 85258 - Scottsdale, AZ/US
  • 8 1, Oncology Venture ApS, 2970 - Hoersholm/DK


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5330


No biomarkers predict efficacy of 5-FU for metastatic colorectal cancer (mCRC). A gene expression based drug response predictor (DRP) had been shown to predict benefit of 5-FU in the PETACC-3 cohort [1]. The current study aimed to validate the biomarker in a cohort of mCRC patients.


100 mCRC patients treated with 5-FU and leucovorin (FLV) at Sahlgrenska University Hospital from 1996-2013 had mRNA isolated from pretreatment formalin-fixed paraffin embedded tumor tissue and run on Affymetrix HG-133_Plus_2 microarray. The DRP is based on correlations of in-vitro cytotoxicity to 5-FU and consequently correlations to mRNA expression of 3.500 tumors and evaluated blinded to outcome. Primary outcome was progression-free-survival (PFS) at 3 years after treatment with FLV. In addition to variables in the table, right vs left colon cancer vs rectal cancer, age, gender and surgery elective or acute were assessed in the multivariate model. Treatments in the metastatic setting included oxaliplatin and irinotecan from year 2000. To correct for possible selection bias for FLV-treatment, we corrected for treatment year 2000 in the analysis plan.


The DRP was able to predict benefit of FLV in patients treated after 2000 (n = 73) with a univariate hazard ratio (HR) of 0.60 (95% confidence interval (CI) 0.38-0.93, p = 0.023) for a 50% difference of the DRP. For patients treated before 2000 results were not statistically significant. In the Cox model including all variables, a DRP score of 90 corresponds to a 50% likelihood of 9 months PFS and a score of 32 corresponds to a PFS of 6 months.Table:

644P Multivariate analysis of PFS

DRP, difference of 50Treatment before 20001.240.52-3.030.63
Treatment after 20000.470.28-0.780.004
Grade of differentiationMedium + high vs low0.480.29-0.800.005
Mucinous vs low0.320.13-0.830.019
Performance status2 vs 0-12.651.41-4.970.002


In patients treated with 5-FU after 2000 the DRP appears to predict benefit. There are no obvious reasons for the lack of prediction before 2000 but options include mRNA degradation, change in handling of samples, or the selection of older patients after 2000. [1] PLOS ONE; 11(5): e0155123.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Oncology Venture.


Oncology Venture.


I.K. Buhl: Full / Part-time employment, Shareholder (immediate family): Oncology Venture. B. Gustavsson: Shareholder / Stockholder / Stock options: Isofol. I.J. Christensen: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Oncology Venture. A. Hansen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Oncology Venture. S. Knudsen: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Oncology Venture. P.B. Jensen: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Oncology Venture. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.